Society on Thrombosis and Haemostasis
Genentech increases investment to $2bn for US manufacturing site
Roche and Genentech have a current commitment of $50bn for US manufacturing
Genentech reports positive trial results for obesity treatment
The treatment is designed to tackle obesity by reducing appetite and regulating blood sugar
Genentech announces positive clinical results for BTK inhibitor MS treatment
Multiple sclerosis affects more than 2.9 million people globally
Genentech starts construction on manufacturing facility in North Carolina, US
The $700m project is part of Roche’s $50bn investment in the US
Roche’s Genentech enters $765m autoimmune disease partnership with Repertoire
The collaboration will leverage Repertoire’s immune mapping DECODE platform
Roche’s Genentech granted FDA approval for TNKase in acute ischaemic stroke
TNKase is the first stroke medicine to be approved by the regulator in almost three decades
Sobi receives NICE recommendation for Altuvoct in severe haemophilia A
Approximately 7,700 people in England are living with the genetic bleeding disorder
Sobi receives MHRA approval for Altuvoct in severe or moderate haemophilia A
The factor VIII replacement therapy has been authorised to treat and prevent bleeding in children and adults
Novo Nordisk’s haemophilia A therapy Mim8 shows promise in late-stage study
The inherited bleeding disorder accounts for up to 85% of the 1,125,000 global haemophilia cases
Roche’s Genentech acquires Regor Pharmaceuticals’ CDK inhibitors for $850m upfront
One of the candidates included in the deal has already shown promise in a phase 1a advanced breast cancer study
Roche’s Genentech and Sangamo enter neurodegenerative disease partnership worth over $1.9bn
According to WHO, neurological conditions are now the leading cause of ill health and disability worldwide
Pfizer shares positive late-stage results for haemophilia A gene therapy
The rare bleeding disorder occurs in approximately 25 in every 100,000 male births globally